Mylan's Troubles Just Won't Stop as Key Insurer Drops EpiPen - (TheStreet via NewsPoints Desk)

  • Cigna revealed that it will not cover Mylan's allergy drug EpiPen on its 2017 formulary, TheStreet reported Wednesday.

  • The insurer instead encouraged patients to use Impax's generic device for treating severe allergic reactions.

  • Mylan CEO Heather Bresch called for an assessment of the healthcare pricing model pricing model and interaction across the entire supply chain.

  • "If I look at five entities that go across the healthcare supply chain, all the discussion has just been around one of those five - the drug manufacturers," Bresch remarked.

  • Mylan faced criticism last year as the price of EpiPen rose to as much as $700 for a two-pack, according to GoodRx, compared to about $200 for a two-pack of Impax's product.

  • Mylan launched a generic version of EpiPen last year at a 50-percent discount, a move Bresch described as "unprecedented" and "responsible."

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.